NO20063677L - Produksjonfremgangsmate - Google Patents
ProduksjonfremgangsmateInfo
- Publication number
- NO20063677L NO20063677L NO20063677A NO20063677A NO20063677L NO 20063677 L NO20063677 L NO 20063677L NO 20063677 A NO20063677 A NO 20063677A NO 20063677 A NO20063677 A NO 20063677A NO 20063677 L NO20063677 L NO 20063677L
- Authority
- NO
- Norway
- Prior art keywords
- mate
- production progress
- 3oxo
- thiophenecarboxamide
- oxiranylmethyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Det beskrives en fremgangsmåte for fremstilling av 5-klor-N-({(5S)-2-okso-3-[4-(3okso-4-morfolinyl)fenyl]-1,3-oksazolidin-5-yl}metyl)-2-tiofenkarboksamid fra 2-[(2S)2-oksiranylmetyl]-1H-isoindo1-1,3(2H)-dion, 4-(4-aminofenyl)-3-morfolinon og 5-klortiofen-2-karbonyl klorid.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102004002044A DE102004002044A1 (de) | 2004-01-15 | 2004-01-15 | Herstellverfahren |
PCT/EP2004/014870 WO2005068456A1 (de) | 2004-01-15 | 2004-12-31 | Herstellverfahren |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20063677L true NO20063677L (no) | 2006-10-11 |
NO335553B1 NO335553B1 (no) | 2014-12-29 |
Family
ID=34716548
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20063677A NO335553B1 (no) | 2004-01-15 | 2006-08-15 | Fremgangsmåte for fremstilling av 5-klor-N-({(5S)-2-okso-3-[4-(3-okso-4-morfolinyl)fenyl]-1,3-oksazolidin-5-yl}metyl)-2-tiofenkarboksamid |
Country Status (33)
Country | Link |
---|---|
US (1) | US7351823B2 (no) |
EP (1) | EP1720866B1 (no) |
JP (2) | JP5311742B2 (no) |
KR (1) | KR20130004257A (no) |
CN (1) | CN1906191B (no) |
AR (1) | AR047389A1 (no) |
AT (1) | ATE518856T1 (no) |
AU (1) | AU2004313694B2 (no) |
BR (1) | BRPI0418405B8 (no) |
CA (1) | CA2553237C (no) |
CY (1) | CY1112565T1 (no) |
DE (1) | DE102004002044A1 (no) |
DK (1) | DK1720866T3 (no) |
EC (1) | ECSP066703A (no) |
ES (1) | ES2369140T3 (no) |
GT (1) | GT200400277A (no) |
HK (1) | HK1103722A1 (no) |
HN (1) | HN2005000016A (no) |
HR (1) | HRP20110796T1 (no) |
IL (1) | IL176767A (no) |
MA (1) | MA28290A1 (no) |
MY (1) | MY138944A (no) |
NO (1) | NO335553B1 (no) |
NZ (1) | NZ548506A (no) |
PE (1) | PE20050763A1 (no) |
PL (1) | PL1720866T3 (no) |
PT (1) | PT1720866E (no) |
RU (1) | RU2383540C2 (no) |
SI (1) | SI1720866T1 (no) |
TW (1) | TWI340137B (no) |
UY (1) | UY28718A1 (no) |
WO (1) | WO2005068456A1 (no) |
ZA (1) | ZA200605747B (no) |
Families Citing this family (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19962924A1 (de) | 1999-12-24 | 2001-07-05 | Bayer Ag | Substituierte Oxazolidinone und ihre Verwendung |
DE10129725A1 (de) | 2001-06-20 | 2003-01-02 | Bayer Ag | Kombinationstherapie substituierter Oxazolidinone |
DE10300111A1 (de) * | 2003-01-07 | 2004-07-15 | Bayer Healthcare Ag | Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid |
DE10355461A1 (de) | 2003-11-27 | 2005-06-23 | Bayer Healthcare Ag | Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung |
DE102004062475A1 (de) * | 2004-12-24 | 2006-07-06 | Bayer Healthcare Ag | Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung |
EP1685841A1 (en) | 2005-01-31 | 2006-08-02 | Bayer Health Care Aktiengesellschaft | Prevention and treatment of thromboembolic disorders |
DE102005045518A1 (de) * | 2005-09-23 | 2007-03-29 | Bayer Healthcare Ag | 2-Aminoethoxyessigsäure-Derivate und ihre Verwendung |
DE102005047558A1 (de) * | 2005-10-04 | 2008-02-07 | Bayer Healthcare Ag | Kombinationstherapie substituierter Oxazolidinone zur Prophylaxe und Behandlung von cerebralen Durchblutungsstörungen |
DE102005047561A1 (de) | 2005-10-04 | 2007-04-05 | Bayer Healthcare Ag | Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung |
RU2578602C2 (ru) * | 2005-10-04 | 2016-03-27 | Байер Интеллектуэль Проперти Гмбх | Способ получения 5-хлор-n-(5s)-2-оксо-3-[4-(3-оксо-морфолинил)-фенил]-1,3-оксазолидин-5-ил}-метил)-2-тиофенкарбоксамида в модификации ii (варианты) |
DE102005047564A1 (de) * | 2005-10-04 | 2007-05-31 | Bayer Healthcare Ag | Amorphe Form von 5-Chlor-N-({(5S)2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl)-methyl)-2-thiophencarboxamid |
DE102006007146A1 (de) | 2006-02-16 | 2007-08-23 | Bayer Healthcare Ag | Aminoacyl-Prodrugs |
DE102006039589A1 (de) * | 2006-08-24 | 2008-03-06 | Bayer Healthcare Ag | Aminoacyl-Prodrugs II |
DE102006051625A1 (de) * | 2006-11-02 | 2008-05-08 | Bayer Materialscience Ag | Kombinationstherapie substituierter Oxazolidinone |
DE102007028319A1 (de) * | 2007-06-20 | 2008-12-24 | Bayer Healthcare Ag | Substituierte Oxazolidinone und ihre Verwendung |
DE102007028407A1 (de) * | 2007-06-20 | 2008-12-24 | Bayer Healthcare Ag | Substituierte Oxazolidinone und ihre Verwendung |
WO2009018807A1 (de) * | 2007-08-06 | 2009-02-12 | Schebo Biotech Ag | Oxazolidinone als faktor xa- inhibitoren, verfahren zu ihrer herstellung und ihre verwendung in der therapie |
US8706950B2 (en) | 2008-03-01 | 2014-04-22 | Kabushiki Kaisha Toshiba | Memory system |
DE102008028071A1 (de) | 2008-06-12 | 2009-12-17 | Bayer Schering Pharma Aktiengesellschaft | Neue Cokristall-Verbindung von Rivaroxaban und Malonsäure |
US20100168111A1 (en) * | 2008-12-31 | 2010-07-01 | Apotex Pharmachem Inc. | Polymorphic form of 5 chloro n {[(5s) 2 oxo 3 [4 (3 oxomorpholin 4 yl)phenyl]oxa-zolidin 5 yl]-methyl}thiophene 2 carboxamide |
US8435989B2 (en) * | 2009-04-28 | 2013-05-07 | Apotex Pharmachem Inc. | Processes for the preparation of rivaroxaban and intermediates thereof |
US8309547B2 (en) * | 2009-04-28 | 2012-11-13 | Apotex Pharmachem Inc. | Processes for the preparation of rivaroxaban and intermediates thereof |
US7816355B1 (en) | 2009-04-28 | 2010-10-19 | Apotex Pharmachem Inc | Processes for the preparation of rivaroxaban and intermediates thereof |
SI2459555T1 (sl) | 2009-07-31 | 2022-03-31 | Krka, D.D., Novo Mesto | Postopek kristalizacije rivaroksabana |
WO2011080341A1 (en) * | 2010-01-04 | 2011-07-07 | Enantia, S.L. | Process for the preparation of rivaroxaban and intermediates thereof |
DE102010028362A1 (de) | 2010-04-29 | 2011-11-03 | Bayer Schering Pharma Aktiengesellschaft | Herstellverfahren |
EP2388260A1 (de) * | 2010-05-21 | 2011-11-23 | Archimica GmbH | Herstellungsverfahren für einen Inhibitor eines Blutgerinnungsfaktors |
CN107021932A (zh) * | 2010-06-29 | 2017-08-08 | 欧美嘉股份有限公司 | 制备5‑左旋‑氨甲基‑3‑芳基‑2‑恶唑烷酮类的方法 |
EP2404920A1 (en) | 2010-07-06 | 2012-01-11 | Sandoz AG | Crystalline form of Rivaroxaban dihydrate |
US20130253187A1 (en) * | 2010-09-14 | 2013-09-26 | Medichem, S.A. | Process for Determining the Suitability for Distribution of a Batch of Thiophene-2-Carboxamide Derivative |
CZ2010714A3 (cs) * | 2010-09-30 | 2012-04-11 | Farmak, A. S. | Zpusob výroby 2-({(5S)-2-oxo-3-[4-(3-oxo-4-morfolinyl)fenyl]-1,3oxazolidin-5-yl}methyl)-1H-isoindol-1,3(2H)-dionu ve vysoké optické cistote |
CA2815063C (en) | 2010-10-18 | 2016-11-22 | Apotex Pharmachem Inc. | Processes for the preparation of rivaroxaban and intermediates thereof |
US9556163B2 (en) * | 2011-05-06 | 2017-01-31 | Egis Gyogyszergyar Nyilvanosan Mukodo Reszvenytarsasag | Process for the preparation of a rivaroxaban and intermediates formed in said process |
WO2012156983A1 (en) * | 2011-05-16 | 2012-11-22 | Symed Labs Limited | Processes for the preparation of 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl) phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide |
ES2395304B1 (es) | 2011-05-20 | 2014-01-16 | Interquim, S.A. | Procedimiento de obtención de una tiofen-2-carboxamida. |
CN102250076A (zh) * | 2011-05-27 | 2011-11-23 | 横店集团家园化工有限公司 | 一种利伐沙班中间体及利伐沙班的制备方法 |
CN102827154B (zh) | 2011-06-14 | 2015-04-22 | 上海科胜药物研发有限公司 | 一种合成利伐沙班中间体4-{4-[(5s)-5-(氨基甲基)-2-氧代-1,3-恶唑烷-3-基]苯基}吗啉-3-酮的方法 |
US20140378682A1 (en) | 2011-09-08 | 2014-12-25 | Cadila Healthcare Limited | Processes and intermediates for preparing rivaroxaban |
WO2013053739A1 (en) | 2011-10-10 | 2013-04-18 | Laboratorios Lesvi, S. L. | Process for preparing factor xa inhibitors |
EP2812329A2 (en) * | 2012-02-06 | 2014-12-17 | Megafine Pharma (P) Ltd. | A process for preparation of rivaroxaban and intermediates thereof |
CZ2012114A3 (cs) * | 2012-02-17 | 2013-02-20 | Zentiva, K.S. | Zpusob prípravy rivaroxabanu zalozený na úspore 1,1´ -karbonyldiimidazolu |
CN103288814B (zh) | 2012-02-24 | 2016-07-06 | 国药集团国瑞药业有限公司 | 一种利伐沙班中间体的制备方法 |
CN102659756A (zh) * | 2012-04-01 | 2012-09-12 | 南京哈柏医药科技有限公司 | 5-氯-2-酰氯噻吩的合成方法 |
WO2013152168A1 (en) | 2012-04-06 | 2013-10-10 | Indiana University Research And Technology Corporation | Processes for preparing rivaroxaban |
US9376427B2 (en) | 2012-05-02 | 2016-06-28 | Symed Labs Limited | Process for preparing rivaroxaban using intermediates |
CN102757424B (zh) * | 2012-07-09 | 2014-10-15 | 云南大学 | 2-苄基取代苯并呋喃—咪唑盐类化合物及其制备方法 |
CN102746288B (zh) * | 2012-07-24 | 2015-04-08 | 常州制药厂有限公司 | 一种抗凝血药及其关键中间体的制备方法 |
WO2014020458A1 (en) * | 2012-08-01 | 2014-02-06 | Alembic Pharmaceuticals Limited | Improved process for preparation of rivaroxaban |
CN102786516B (zh) * | 2012-08-21 | 2014-10-01 | 湖南师范大学 | 一种利伐沙班的合成方法 |
CN103833724A (zh) * | 2012-11-20 | 2014-06-04 | 上海医药工业研究院 | 一种5-氯噻吩-2-甲酰氯的制备方法 |
CN103864772A (zh) * | 2012-12-13 | 2014-06-18 | 北京京卫信康医药科技发展有限公司 | 一种利伐沙班及其中间体的制备方法 |
CN103864771A (zh) * | 2012-12-13 | 2014-06-18 | 北京京卫信康医药科技发展有限公司 | 一种利伐沙班的制备方法 |
PT2935255T (pt) * | 2012-12-21 | 2017-11-21 | D O O Farma Grs | Processo para a preparação de rivaroxaban |
DK2895176T3 (en) | 2012-12-26 | 2017-01-30 | Wanbury Ltd | RIVAROXABAN INTERMEDIATE PRODUCTS AND MANUFACTURING THEREOF |
JP2016504348A (ja) | 2012-12-26 | 2016-02-12 | ワンブリー リミテッド | 置換オキサゾリジノンのアルデヒド誘導体 |
WO2014155259A2 (en) | 2013-03-25 | 2014-10-02 | Glenmark Pharmaceuticals Limited; Glenmark Generics Limited | Process for the preparation of rivaroxaban |
CN104109158A (zh) * | 2013-04-16 | 2014-10-22 | 上海医药工业研究院 | 一种纯化利伐沙班的方法 |
CN103275061A (zh) * | 2013-06-04 | 2013-09-04 | 上海同昌生物医药科技有限公司 | 一种生产5-氯噻吩-2-羧酸的方法 |
CN103351385A (zh) * | 2013-06-28 | 2013-10-16 | 浙江燎原药业有限公司 | 一种利伐沙班中间体的制备方法 |
CN103709116B (zh) * | 2013-12-10 | 2015-09-23 | 四川大学 | 一种4-(4-烷氧羰氨基)苯基-3-吗啉酮的制备方法 |
CN103724336B (zh) * | 2013-12-24 | 2015-10-21 | 悦康药业集团有限公司 | 一种新型抗凝血药物的合成方法 |
WO2015104605A1 (en) | 2014-01-08 | 2015-07-16 | Wockhardt Limited | A process for preparing rivaroxaban or a pharmaceutically acceptable salt thereof |
WO2015111076A2 (en) | 2014-01-23 | 2015-07-30 | Symed Labs Limited | Improved processes for the preparation of highly pure rivaroxaban crystal modification i |
CN105085370B (zh) * | 2014-04-22 | 2017-04-12 | 北大方正集团有限公司 | (s)‑1‑卤代‑2‑[2‑(1,3‑二氧异吲哚)基]乙基氯甲酸酯及其制备方法 |
CN105693746B (zh) * | 2014-06-14 | 2018-09-14 | 广东东阳光药业有限公司 | 噁唑烷酮类化合物的制备方法及其中间体 |
CN104086539A (zh) * | 2014-07-17 | 2014-10-08 | 天津炜捷制药有限公司 | 一种利伐沙班的制备方法 |
CN104211693B (zh) * | 2014-08-07 | 2017-02-22 | 成都百裕制药股份有限公司 | 一种利伐沙班晶型及其制备方法与用途 |
CN104211694A (zh) * | 2014-08-14 | 2014-12-17 | 广东东阳光药业有限公司 | 一种改进的制备Xa因子抑制剂的方法 |
EP3186246A1 (en) * | 2014-08-25 | 2017-07-05 | Cipla Limited | Process for the preparation of rivaroxaban |
EA034656B1 (ru) | 2014-10-22 | 2020-03-03 | Закляды Фармацеутычне Польфарма С.А | Способ получения полиморфа ривароксабана |
CN104807934B (zh) * | 2015-04-30 | 2017-01-18 | 成都百裕制药股份有限公司 | 异吲哚二酮类化合物的正相高效液相色谱检测方法 |
CN105130976A (zh) * | 2015-08-26 | 2015-12-09 | 浙江车头制药股份有限公司 | 一种利伐沙班中间体的合成方法 |
CN105440028B (zh) * | 2015-12-07 | 2018-03-13 | 石家庄康贺威药业有限公司 | 一种利伐沙班化合物及其制备方法 |
CN106008490B (zh) * | 2016-01-11 | 2019-01-04 | 南京生命能科技开发有限公司 | 一种利伐沙班的新晶体及其制备方法 |
CN106977507A (zh) * | 2017-04-21 | 2017-07-25 | 上海华源医药科技发展有限公司 | 一种利伐沙班的制备方法 |
CN109553611A (zh) * | 2017-09-23 | 2019-04-02 | 齐鲁制药有限公司 | 利伐沙班中间体的制备方法和用途 |
JP7205529B2 (ja) * | 2018-02-26 | 2023-01-17 | 住友化学株式会社 | オキサゾリジノン化合物の製造方法 |
JP7339754B2 (ja) * | 2019-03-27 | 2023-09-06 | ダイト株式会社 | 中間体の製造方法 |
CN112521380A (zh) * | 2020-12-14 | 2021-03-19 | 哈尔滨珍宝制药有限公司 | 一种利伐沙班中间体a的合成方法及其在制备利伐沙班中的应用 |
KR20240013784A (ko) * | 2021-05-28 | 2024-01-30 | 머크 샤프 앤드 돔 엘엘씨 | Btk 억제제 및 그의 중간체의 합성 |
EP4201933A1 (en) | 2021-12-23 | 2023-06-28 | Zaklady Farmaceutyczne Polpharma S.A. | Crystallisation process for rivaroxaban |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19962924A1 (de) * | 1999-12-24 | 2001-07-05 | Bayer Ag | Substituierte Oxazolidinone und ihre Verwendung |
DE10129725A1 (de) * | 2001-06-20 | 2003-01-02 | Bayer Ag | Kombinationstherapie substituierter Oxazolidinone |
DE10300111A1 (de) * | 2003-01-07 | 2004-07-15 | Bayer Healthcare Ag | Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid |
-
2004
- 2004-01-15 DE DE102004002044A patent/DE102004002044A1/de not_active Withdrawn
- 2004-12-29 GT GT200400277A patent/GT200400277A/es unknown
- 2004-12-31 ES ES04804455T patent/ES2369140T3/es active Active
- 2004-12-31 CA CA2553237A patent/CA2553237C/en active Active
- 2004-12-31 CN CN200480040552XA patent/CN1906191B/zh active Active
- 2004-12-31 PL PL04804455T patent/PL1720866T3/pl unknown
- 2004-12-31 RU RU2006129341/04A patent/RU2383540C2/ru not_active IP Right Cessation
- 2004-12-31 AU AU2004313694A patent/AU2004313694B2/en active Active
- 2004-12-31 JP JP2006548182A patent/JP5311742B2/ja active Active
- 2004-12-31 SI SI200431764T patent/SI1720866T1/sl unknown
- 2004-12-31 EP EP04804455A patent/EP1720866B1/de active Active
- 2004-12-31 NZ NZ548506A patent/NZ548506A/en unknown
- 2004-12-31 KR KR1020127018712A patent/KR20130004257A/ko not_active Application Discontinuation
- 2004-12-31 PT PT04804455T patent/PT1720866E/pt unknown
- 2004-12-31 BR BRPI0418405A patent/BRPI0418405B8/pt active IP Right Grant
- 2004-12-31 WO PCT/EP2004/014870 patent/WO2005068456A1/de active Application Filing
- 2004-12-31 DK DK04804455.6T patent/DK1720866T3/da active
- 2004-12-31 AT AT04804455T patent/ATE518856T1/de active
-
2005
- 2005-01-10 US US11/032,815 patent/US7351823B2/en active Active
- 2005-01-12 UY UY28718A patent/UY28718A1/es active IP Right Grant
- 2005-01-13 HN HN2005000016A patent/HN2005000016A/es unknown
- 2005-01-13 MY MYPI20050142A patent/MY138944A/en unknown
- 2005-01-14 PE PE2005000062A patent/PE20050763A1/es active IP Right Grant
- 2005-01-14 AR ARP050100147A patent/AR047389A1/es not_active Application Discontinuation
- 2005-01-14 TW TW094101059A patent/TWI340137B/zh active
-
2006
- 2006-07-10 IL IL176767A patent/IL176767A/en active IP Right Grant
- 2006-07-10 MA MA29179A patent/MA28290A1/fr unknown
- 2006-07-12 ZA ZA200605747A patent/ZA200605747B/en unknown
- 2006-07-14 EC EC2006006703A patent/ECSP066703A/es unknown
- 2006-08-15 NO NO20063677A patent/NO335553B1/no unknown
-
2007
- 2007-07-20 HK HK07107855.2A patent/HK1103722A1/xx unknown
-
2011
- 2011-10-27 CY CY20111101020T patent/CY1112565T1/el unknown
- 2011-11-02 HR HR20110796T patent/HRP20110796T1/hr unknown
- 2011-12-27 JP JP2011286538A patent/JP2012097106A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20063677L (no) | Produksjonfremgangsmate | |
NO20082059L (no) | Ny polymorf form og den amorfe formen av 5-klor-N({(5S)-2-okso-3[4-(3-okso-4-morfolinyl)-fenyl]-1,3-oksazolidin-5-yl}-metyl)-2-tiofenkarboksamid | |
MY138386A (en) | Process for the preparation of a solid, orally administrable pharmaceutical composition | |
HK1130252A1 (en) | Aminoacyl prodrug derivatives and medicaments for the treatment of thromboembolitic disorders | |
HK1157759A1 (en) | New co-crystal compound of rivaroxaban and malonic acid | |
MY143999A (en) | Solid, modified-release pharmaceutical dosage forms which can be administered orally | |
ZA200802871B (en) | Novel polymorphous form and the amorphous form of 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidine-5-yl}-methyl)-2-thiophene carboxamide | |
DOP2004001066A (es) | Procedimiento de preparacion | |
CU23445A3 (es) | Procedimiento de preparación | |
UA84591C2 (en) | Process for the preparation of 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidine-5-yl}-methyl)-2-thiophene carboxamide | |
UA94428C2 (en) | Polymorphous form and the amorphous form of 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidine-5-yl}-methyl)-2-thiophene carboxamide | |
TH79777B (th) | กระบวนการเตรียม | |
DOP2004001034A (es) | Procedimiento para la preparacion de una composicion farmaceutica solida administrable oralmente que comprende 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morfolinil)-fenil]-1,3-oxazolidin-5-il}-metil)-2-tiofencarboxamida en forma hidrofilizada | |
UY28628A1 (es) | Procedimiento para la preparación de una composición farmacéutica sólida administrable oralmente | |
TH145210A (th) | กระบวนการสำหรับการเตรียมองค์ประกอบทางเภสัชกรรมของแข็งที่สามารถให้ทางปากได้(Process for the Preparation of A solid, Orally Adminnistrable Pharmaceutical Composition) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: BAYER INTELLECTUAL PROPERTY GMBH, DE |
|
CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: BAYER INTELLECTUAL PROPERTY GMBH, DE |